Abstract
The novel combination of checkpoint inhibitors targeting the PD(L)1 pathway and anti-VEGFA therapy has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC). However, biomarkers predictive of response to these therapies are still lacking, representing a major clinical challenge. See related articles by Zhang et al., p. 3499, and Zhu et al., p. 3537.